Vinod S. Hegade
YOU?
Author Swipe
View article: Neurosteroid Activation of GABA-A Receptors: A Potential Treatment Target for Symptoms in Primary Biliary Cholangitis?
Neurosteroid Activation of GABA-A Receptors: A Potential Treatment Target for Symptoms in Primary Biliary Cholangitis? Open
Background and Aims. A third of patients with primary biliary cholangitis (PBC) experience poorly understood cognitive symptoms, with a significant impact on quality of life (QOL), and no effective medical treatment. Allopregnanolone, a ne…
View article: UK-Wide Multicenter Evaluation of Second-line Therapies in Primary Biliary Cholangitis
UK-Wide Multicenter Evaluation of Second-line Therapies in Primary Biliary Cholangitis Open
Across the population of patients with primary biliary cholangitis in the United Kingdom, rates of biochemical response and drug discontinuation appear similar under fibric acid and OCA treatment.
View article: Factors predicting 30-day mortality after ERCP in patients with inoperable malignant hilar biliary obstruction: a single tertiary referral centre experience and systematic review
Factors predicting 30-day mortality after ERCP in patients with inoperable malignant hilar biliary obstruction: a single tertiary referral centre experience and systematic review Open
Objective There is a paucity of studies in the literature body evaluating short term outcomes following endoscopic retrograde cholangiopancreatography (ERCP) in patients with inoperable malignant hilar biliary obstruction (MHBO). We aimed …
View article: Intraductal fully covered self-expanding metal stents in the management of post-liver transplant anastomotic strictures: a UK wide experience
Intraductal fully covered self-expanding metal stents in the management of post-liver transplant anastomotic strictures: a UK wide experience Open
Background: Fully covered intraductal self-expanding metal stents (IDSEMS) have been well described in the management of post-liver transplant (LT) anastomotic strictures (ASs). Their antimigration waists and intraductal nature make them s…
View article: PTU-3 Endoscopic palliation and prognostication of malignant hilar biliary strictures: A single centre experience
PTU-3 Endoscopic palliation and prognostication of malignant hilar biliary strictures: A single centre experience Open
Introduction The optimum approach to palliation of malignant hilar biliary strictures (MHBS) is unclear. National UK Hospital Episode Statistics data demonstrates 30-day mortality of > 20% following endoscopic and percutaneous stenting.1,2…
View article: OWE-6 Multicentre evaluation of second line therapies in primary biliary cholangitis: UK experience
OWE-6 Multicentre evaluation of second line therapies in primary biliary cholangitis: UK experience Open
Introduction Our aim was to compare the effectiveness of second-line therapies in primary biliary cholangitis (PBC), with regards Obeticholic acid (OCA) and non-licensed therapy (fibric acid derivatives; FA) across a nationwide cohort of p…
View article: P065 Genetic evaluation of patients listed for liver transplantation with cryptogenic cirrhosis
P065 Genetic evaluation of patients listed for liver transplantation with cryptogenic cirrhosis Open
Introduction Identifying the underlying cause of liver disease is important, however in 5–30% of patients with cirrhosis no cause can be found, which is referred to as cryptogenic cirrhosis (CC). From registry data 4% of liver transplants …
View article: The Serum Proteome and Ursodeoxycholic Acid Response in Primary Biliary Cholangitis
The Serum Proteome and Ursodeoxycholic Acid Response in Primary Biliary Cholangitis Open
Background and Aims Stratified therapy has entered clinical practice in primary biliary cholangitis (PBC), with routine use of second‐line therapy in nonresponders to first‐line therapy with ursodeoxycholic acid (UDCA). The mechanism for n…
View article: O70 Patient reported experiences through PBC foundation app: what impacts upon a PBC patient’s experience?
O70 Patient reported experiences through PBC foundation app: what impacts upon a PBC patient’s experience? Open
Intro The PBC Foundation is a UK-based patient support organisation which supports patients with PBC in over 75 countries, affected by Primary Biliary Cholangitis (PBC). The PBC Foundation has developed a self-management App to conduct sur…
View article: P38 Leeds teaching hospitals NHS trust experience of obeticholic acid therapy over a 15 month time period
P38 Leeds teaching hospitals NHS trust experience of obeticholic acid therapy over a 15 month time period Open
Introduction Obeticholic Acid (OCA) is a treatment option for primary biliary cholangitis which became available to the NHS in 2017 following NICE approval. The main clinical trial for OCA (called POISE) was based on patients receiving the…
View article: Pruritus secondary to primary biliary cholangitis
Pruritus secondary to primary biliary cholangitis Open
Primary biliary cholangitis (PBC) is a long‐term disease affecting 35 in every 100,000 people in the United Kingdom (UK) and United States. It is driven by the immune system and causes inflammation of bile ducts (tubes carrying bile from t…
View article: Management of Fatigue in Primary Biliary Cholangitis
Management of Fatigue in Primary Biliary Cholangitis Open
Fatigue in primary biliary cholangitis patients is a frequently encountered and often debilitating symptom. With no currently approved drug therapies available to target fatigue as a symptom, managing these patients can be very challenging…
View article: Autotaxin, bile acid profile and effect of ileal bile acid transporter inhibition in primary biliary cholangitis patients with pruritus
Autotaxin, bile acid profile and effect of ileal bile acid transporter inhibition in primary biliary cholangitis patients with pruritus Open
Background and Aims Pruritus is a common symptom in patients with primary biliary cholangitis (PBC) for which ileal bile acid transporter (IBAT) inhibition is emerging as a potential therapy. We explored the serum metabonome and gut microb…
View article: Diagnosis and management of IgG4-related disease
Diagnosis and management of IgG4-related disease Open
IgG subclass 4-related disease (IgG4-RD) is a rare but increasingly recognised fibroinflammatory condition known to affect multiple organs. IgG4-RD is characterised by unique histological features of lymphoplasmacytic infiltration, storifo…
View article: PTH-038 Management of biliary complications following liver transplantation: 10 years experience
PTH-038 Management of biliary complications following liver transplantation: 10 years experience Open
Introduction Biliary complications after liver transplantation (LT) are common and some risk factors have been identified. Optimum endoscopic management including use of fully covered self-expanding metal stents (fcSEMS) in patients follow…
View article: Novel bile acid therapeutics for the treatment of chronic liver diseases
Novel bile acid therapeutics for the treatment of chronic liver diseases Open
Recent developments in understanding the role of bile acids (BAs) as signalling molecules in human metabolism and inflammation have opened new avenues in the field of hepatology research. BAs are no longer considered as simple molecules he…